Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > Sirnaomics Licenses Polypeptide Nanoparticle Technology for Its siRNA Therapeutic Product Development

Sirnaomics, Inc. announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School. The licensing agreement grants Sirnaomics exclusive rights to a patent covering use of Histidine-Lysine polymer (HKP) for siRNA therapeutics in the areas of wound healing and ocular diseases (U.S. patent application 60/173,576 filed December 29, 1999).

Sirnaomics Licenses Polypeptide Nanoparticle Technology for Its siRNA Therapeutic Product Development

Gaithersburg, MD | Posted on January 13th, 2010

Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases.

RNAi plays a multifunctional role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and, in its best-studied mode of action, reducing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in many basic research, drug discovery and clinical settings. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions, investments and mergers have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutics development. Consequently, there are more than a dozen clinical trials currently ongoing for various therapeutic applications of RNAi.

Sirnaomics' mission is to advance RNAi technology for rapid development of novel siRNA therapeutics. The company's proprietary "Tri-Blocker" technology for multi-targeted siRNA cocktail design is reflecting the unique advantage of siRNA-based active pharmaceutical ingredient (API) in knocking down multiple disease-causing genes in the same treatment. Through in-house efforts and collaborations, Sirnaomics is developing nanoparticle-based siRNA delivery systems in three generations: the self-assembled nanoparticles (1st), ligand-directed nanoparticles (2nd), and infrared-activated nanoparticles (3rd), for various types of therapeutic applications. The "Snano" series of the company's siRNA delivery technology are representing the 1st generation and will be complemented by the addition of the licensed HKP technology.

"Licensing the Histidine-Lysine polymer nanoparticle technology is rooted in our long time experience and in-depth understanding of this unique class of polypeptides as an siRNA delivery vehicle. The two year collaboration between Dr. Mixson and Sirnaomics, supported by a Maryland Industrial Partnerships (MIPS) grant, facilitated progress of our scarless wound healing program and resulted in the discovery and development of STP705 (Cutasil®)," said the President and CEO of the company, Dr. Patrick Y. Lu. "The collaboration and licensing agreement have provided an important foundation for Sirnaomics' technology and product development. We are currently engaging in several similar collaborative efforts and we believe that this is a great way to create value and ensure the credibility of a novel technology."

"STP705 is a topically applied formulation for delivery of the siRNAs to the wound site and it has demonstrated accelerated wound repair yet with reduced scar formation in both murine and swine excisional wound models." explained Dr. David Evans, the company's vice president for discovery research. "The remarkable therapeutic benefits of STP705 in these models have clearly demonstrated the power of HKP for in vivo siRNA delivery and, based on our extensive data set we are actively seeking partnerships to drive STP705 to the market". The exciting experimental results will be reported during the upcoming Keystone Symposia "RNA Silencing: Mechanism, Biology and Application" on January 14-19, 2010.


About Sirnaomics
Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established in 2007 by a group of leading scientists in the field of RNAi technology, the company is pursuing the mission of advancing RNAi technology with novel targeted therapeutics development. In 2008, the company established its subsidiary in Suzhou, China to expand its R&D capacity and potential market. Members of the senior management team bring over 60 years of combined experience in the biopharmaceutical, financial and business management industries. Supported with funding from founders, angel investors, government grants and China-Singapore VC, Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of interest include wound healing, pandemic flu (H5N1/H1N1), ocular diseases, oncology, spinal cord injury and transplantation.

For more information, please click here

George J. Ji
Sirnaomics, Inc.
401 Professional Drive, Suite 130
Gaithersburg, MD 20879, USA
301-740-1730 Phone
301-740-1731 FAX

Copyright © Sirnaomics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists found a natural nanostructure to control the flow of light October 4th, 2015

Horizontal magnetic tunneling in a field-effect device integrated on Silicon October 3rd, 2015

Crystal clear: Thousand-fold fluorescence enhancement in an all-polymer thin film: Griffith University researchers report breakthrough due to novel and multi-layer Colloidal Photonic Crystal structure October 2nd, 2015

Industrial Nanotech, Inc. Announces New Office in Arizona to Service the Company's New Regional and National Home Builders in Arizona and Nevada October 2nd, 2015


Sniffing out cancer with improved 'electronic nose' sensors October 2nd, 2015

Hopes of improved brain implants October 1st, 2015

New Nanomaterials Taking Research to Mexico, Possibly into Space September 29th, 2015

Cristal Therapeutics Starts Clinical Phase I Trial with Nanomedicine CriPec® Docetaxel in Patients with Solid Tumours September 29th, 2015


Scientists found a natural nanostructure to control the flow of light October 4th, 2015

Industrial Nanotech, Inc. Announces New Office in Arizona to Service the Company's New Regional and National Home Builders in Arizona and Nevada October 2nd, 2015

Production of High Temperature Ceramics with Modified Properties in Iran October 2nd, 2015

ISO Approves 2 Int'l Nanotechnology-Related Standards Proposed by Iran October 2nd, 2015

Patents/IP/Tech Transfer/Licensing

Graphene Has a Place on the Hype Cycle, Says European Flagship Director October 1st, 2015

Wearable electronic health patches may now be cheaper and easier to make September 30th, 2015

An engineered surface unsticks sticky water droplets August 31st, 2015

Developing Component Scale Composites Using Nanocarbons August 26th, 2015


Hopes of improved brain implants October 1st, 2015

A new single-molecule tool to observe enzymes at work September 28th, 2015

DNA-based nanodevices for molecular medicine: Self-assembled DNA nanostructures can be used in molecular-scale diagnostics and as smart drug-delivery vehicles. September 25th, 2015

Los Alamos explores hybrid ultrasmall gold nanocluster for enzymatic fuel cells: New technique removes barrier to development of biofuel cells with efficient performance September 25th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic